Announcing a new publication for Acta Materia Medica journal. Monoamine oxidase (MAO) is a useful target in the treatment of neurodegenerative diseases and depressive disorders. Understanding the ...

The following is written by Sheldon S. Sones, RPh, FASCP, President, Sheldon S. Sones and Associates. Monoamine oxidase inhibitors (MAO inhibitors or MAOIs) are drugs which, by virtue of their ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, and safety of rasagiline are reviewed. Summary: Rasagiline is a novel, investigational propargylamine that irreversibly and selectively ...

Monoamine oxidase inhibitors (MAOIs) have a long and prosperous history as medications for major depressive disorder (MDD). But this type of antidepressant has mostly seen its day. Though MAOIs are ...

Neurobiogen Co Ltd. has synthesized monoamine oxidase-B (MAO-B) inhibitors reported to be useful for the treatment of Parkinson’s disease.

Miralogx LLC and Mira Pharmaceuticals Inc. have jointly disclosed new cannabinoid analogues acting as monoamine oxidase-A (MAO-A) and/or MAO-B inhibitors reported to be useful for the treatment of ...

In the years after World War II, there were no effective medicines for schizophrenia, bipolar disorder, or major depression. There were not even names for such things. The word ‘antipsychotic’ was ...

Dopamine agonists and dopamine reuptake inhibitors (DRIs) appear to have equal efficacy for Parkinson's disease (PD) and motor fluctuations uncontrolled by levodopa. However, some DRIs are more ...